second activator signal of a physiological T cell response (Van Der Stegen et al.

2015).

Fig. 25.1 Chimeric antigen receptor T cell (CAR-T) therapy. In CAR-T therapy, initially the T

cells are collected from the patient’s blood. Subsequently, these autologous T cells are genetically

engineered to express CARs on the cell surface. The engineered CAR T cells are expanded in the

laboratory to generate millions of CAR-transduced T cells, which are then infused in a process

similar to blood transfusion in the MM patients

Fig. 25.2 Chimeric antigen receptor

25

Chimeric Antigen Receptor T Cell Therapy: A Cutting-Edge Therapy for. . .

477